Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor.

DOTATOC Peptide receptor radionuclide therapy Phosphaturic mesenchymal tumor Radiofrequency ablation Tumor-induced osteomalacia

Journal

Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601

Informations de publication

Date de publication:
Historique:
received: 15 07 2020
accepted: 19 07 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 15 1 2021
Statut: epublish

Résumé

Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting syndrome. Upon complete surgical removal of the tumor, FGF-23 normalizes and the osteomalacia is cured. In cases in which surgery is not feasible, radiofrequency ablation (RFA) is the treatment of choice. We describe a case with a PMT situated in the sacrum, in close proximity to the sacral plexus. Both surgery and RFA were considered potentially nerve damaging. Since the tumor showed expression of somatostatin receptors, we opted for a peptide receptor radionuclide therapy (PRRT) with

Identifiants

pubmed: 33442358
doi: 10.1159/000510334
pii: cro-0013-1373
pmc: PMC7772845
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1373-1380

Informations de copyright

Copyright © 2020 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

J Endocr Soc. 2017 May 03;1(6):726-730
pubmed: 29264524
N Engl J Med. 2001 Dec 27;345(26):1883-8
pubmed: 11756579
Endocr Connect. 2019 Oct;8(10):1330-1353
pubmed: 31505461
Bone Rep. 2017 Sep 20;7:90-97
pubmed: 29021995
Clin Endocrinol (Oxf). 2016 Jan;84(1):134-40
pubmed: 25996566
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
N Engl J Med. 2002 May 30;346(22):1748-9; author reply 1748-9
pubmed: 12037159
JBMR Plus. 2019 Feb 28;3(7):e10178
pubmed: 31372587
Arthritis Rheum. 2008 Mar;58(3):773-7
pubmed: 18311810
Asian Pac J Cancer Prev. 2014;15(24):10997-8
pubmed: 25605218
JAMA. 2005 Sep 14;294(10):1260-7
pubmed: 16160135
J Nucl Med Technol. 2016 Dec;44(4):248-250
pubmed: 27634982
J Bone Miner Res. 2004 Mar;19(3):429-35
pubmed: 15040831
World J Surg Oncol. 2016 Jan 08;14(1):4
pubmed: 26744291

Auteurs

Simon Häfliger (S)

Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Ann-Katrin Seidel (AK)

Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Eric Schoch (E)

Department of Radiology, Kantonsspital Winterthur, Winterthur, Switzerland.

Jan Reichmann (J)

Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.

Damian Wild (D)

Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.

Stephanie Steinmann-Schwager (S)

Hausärzte am Bahnhofplatz, General Medicine Office, Winterthur, Switzerland.

Miklos Pless (M)

Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Classifications MeSH